The company said that the claims allowed cover the use of some important gene sequences in blood sample for detection and monitoring of breast cancer. The patent will be valid until 2025.
Family 3 patents have earlier been granted in US and Europe.
DiaGenic develops more patient friendly methods for early detection of diseases.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia